This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
HRC or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRC vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Boston Scientific (BSX) closed at $37.67 in the latest trading session, marking a +1.7% move from the prior day.
HRC or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRC vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Boston Scientific (BSX) closed at $34.60 in the latest trading session, marking a +1.62% move from the prior day.
Boston Scientific's (BSX) $4.2B Buyout to Augment PI Business
by Zacks Equity Research
Boston Scientific (BSX) continues to expand on the back of its inorganic growth strategy. The latest takeover is expected to boost the PI business.
Edwards Lifesciences' CE Mark for SAPIEN 3 Boosts THVT Arm
by Zacks Equity Research
Latest CE Mark receipt is expected to fortify Edwards Lifesciences' (EW) position in Europe.
Boston Scientific (BSX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Boston Scientific (BSX) closed at $36.48, marking a +0.75% move from the previous day.
Boston Scientific (BSX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Boston Scientific (BSX) closed at $38.60, marking a +0.42% move from the previous day.
HRC vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. BSX: Which Stock Is the Better Value Option?
Q3 Earnings Mixed
by Zacks Equity Research
Q3 Earnings Mixed
Boston Scientific (BSX) Beats on Q3 Earnings, Misses Revenues
by Zacks Equity Research
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q3.
Boston Scientific (BSX) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.94% and -0.58%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Q3 Earnings on Oct 24: BSX, ALGN & More
by Zacks Equity Research
Long-term potential of the Medical Products industry appears promising at the moment amid certain short-term geopolitical insecurities.
Should You Buy Boston Scientific (BSX) Ahead of Earnings?
by Zacks Equity Research
Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Most Spectacular Earnings Charts This Week
by Tracey Ryniec
Investors aren't spooked in these stocks. They have great earnings track records and shares are trading near their highs.
BAX vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BAX vs. BSX: Which Stock Is the Better Value Option?
Will Boston Scientific's (BSX) Q3 Earnings Reflect Overall Gain?
by Zacks Equity Research
We are optimistic about the IC business that will help Boston Scientific (BSX) maintain impressive global growth, owing to an innovative portfolio and robust commercial teams.
Boston Scientific (BSX) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Boston Scientific Stock Now
by Zacks Equity Research
Boston Scientific (BSX) is coming up with better-than-expected earnings and revenue performances on the back of growth across all business lines and geographies.
Why Boston Scientific (BSX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Boston Scientific Grows on Acquisitions, Product Launches
by Zacks Equity Research
Boston Scientific's (BSX) strategy to extend its existing portfolio through inorganic growth profile has been advancing well. Further, this should help aid the company's top line in the long term.
Baxter (BAX) Collaborates With USC CBC to Digitize Healthcare
by Zacks Equity Research
Baxter's (BAX) efforts to digitize healthcare solutions are likely to fortify its foothold in the highly competitive MedTech industry.
Boston Scientific Thrives in Urology on New LithoVue Empower
by Zacks Equity Research
Boston Scientific's (BSX) combination of LithoVue Empower and LithoVue Single-Use Digital Ureteroscope will put the whole stone manipulation procedure in the operating surgeon's hands.
Boston Scientific's FDA Nod for Eluvia Stent Expands PI Suite
by Zacks Equity Research
Boston Scientific's (BSX) PMA approval for Eluvia Drug-Eluting Vascular Stent System will help boost the top line at the PI business.
Boston Scientific to Boost MedSurg Unit Via Augmenix Buyout
by Zacks Equity Research
Boston Scientific (BSX) continues to adopt organic as well as inorganic means to boost top line.